HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Positron emission tomography imaging of CD105 expression with 89Zr-Df-TRC105.

AbstractPURPOSE:
High tumor microvessel density correlates with a poor prognosis in multiple solid tumor types. The clinical gold standard for assessing microvessel density is CD105 immunohistochemistry on paraffin-embedded tumor specimens. The goal of this study was to develop an (89)Zr-based PET tracer for noninvasive imaging of CD105 expression.
METHODS:
TRC105, a chimeric anti-CD105 monoclonal antibody, was conjugated to p-isothiocyanatobenzyl-desferrioxamine (Df-Bz-NCS) and labeled with (89)Zr. FACS analysis and microscopy studies were performed to compare the CD105 binding affinity of TRC105 and Df-TRC105. PET imaging, biodistribution, blocking, and ex-vivo histology studies were performed on 4T1 murine breast tumor-bearing mice to evaluate the pharmacokinetics and tumor-targeting of (89)Zr-Df-TRC105. Another chimeric antibody, cetuximab, was used as an isotype-matched control.
RESULTS:
FACS analysis of HUVECs revealed no difference in CD105 binding affinity between TRC105 and Df-TRC105, which was further validated by fluorescence microscopy. (89)Zr labeling was achieved with high yield and specific activity. Serial PET imaging revealed that the 4T1 tumor uptake of (89)Zr-Df-TRC105 was 6.1 ± 1.2, 14.3 ± 1.2, 12.4 ± 1.5, 7.1 ± 0.9, and 5.2 ± 0.3 %ID/g at 5, 24, 48, 72, and 96 h after injection, respectively (n = 4), higher than all organs starting from 24 h after injection, which provided excellent tumor contrast. Biodistribution data as measured by gamma counting were consistent with the PET findings. Blocking experiments, control studies with (89)Zr-Df-cetuximab, and ex-vivo histology all confirmed the in vivo target specificity of (89)Zr-Df-TRC105.
CONCLUSION:
We report here the first successful PET imaging of CD105 expression with (89)Zr as the radiolabel. Rapid, persistent, CD105-specific uptake of (89)Zr-Df-TRC105 in the 4T1 tumor was observed.
AuthorsHao Hong, Gregory W Severin, Yunan Yang, Jonathan W Engle, Yin Zhang, Todd E Barnhart, Glenn Liu, Bryan R Leigh, Robert J Nickles, Weibo Cai
JournalEuropean journal of nuclear medicine and molecular imaging (Eur J Nucl Med Mol Imaging) Vol. 39 Issue 1 Pg. 138-48 (Jan 2012) ISSN: 1619-7089 [Electronic] Germany
PMID21909753 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, U.S. Gov't, Non-P.H.S.)
Chemical References
  • 4-isothiocyanatobenzyl-desferrioxamine
  • Antibodies, Monoclonal
  • Antigens, CD
  • ENG protein, human
  • Isothiocyanates
  • Radioisotopes
  • Receptors, Cell Surface
  • Zirconium
  • Deferoxamine
Topics
  • Animals
  • Antibodies, Monoclonal (chemistry, diagnostic use, pharmacokinetics)
  • Antigens, CD (metabolism)
  • Cell Line, Tumor
  • Deferoxamine (analogs & derivatives, chemistry)
  • Female
  • Gene Expression Regulation, Neoplastic
  • Humans
  • Isothiocyanates (chemistry)
  • Mice
  • Positron-Emission Tomography (methods)
  • Radioisotopes (diagnostic use)
  • Receptors, Cell Surface (metabolism)
  • Zirconium (diagnostic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password:


Research Interface PRO additionally includes drill-down to evidence, articles by author, export to Excel, FDA Link and mobile subscription:
1 year subscription, $490.00 USD